🇺🇸 FDA
Patent

US 6066642

Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists

expired A61PA61P25/22A61P29/00

Quick answer

US patent 6066642 (Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 23 2000 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
33
CPC classes
A61P, A61P25/22, A61P29/00, A61P43/00, A61P7/02